Article
Lidoflazine is a high affinity blocker of the HERG K(+)channel.
Journal of molecular and cellular cardiology - 1 May 2004
Ridley John M, Dooley Philip C, Milnes James T, Witchel Harry J, Hancox Jules C
Abstract excerpt
Lidoflazine is an antianginal calcium channel blocker that carries a significant risk of QT interval prolongation and ventricular arrhythmia. We investigated whether or not lidoflazine inhibits current through the rapid delayed rectifier K(+) channel alpha subunit (encoded by HERG - human ether-a-go-go-related gene), since this channel has been widely linked to drug-induced QT-prolongation. Lidoflazine inhibited...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
